Stocktoria
Cabaletta Bio, Inc. CABA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2019-10-25
Chart by TradingView
1/9
Piotroski F — financial health
-11.48
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$172.2M | -$125.1M | -$74.7M | -$54.1M | -$46.3M |
| Net income | -$167.9M | -$115.9M | -$67.7M | -$53.0M | -$46.3M |
| Operating cash flow | -$131.1M | -$88.2M | -$53.5M | -$46.4M | -$34.1M |
| Free cash flow | -$132.3M | -$90.4M | -$54.2M | -$48.8M | -$35.3M |
| Total assets | $165.1M | $185.0M | $253.7M | $117.0M | $126.3M |
| Total liabilities | $53.0M | $32.7M | $17.5M | $12.4M | $8.4M |
| Shareholders' equity | $112.1M | $152.3M | $236.2M | $104.5M | $118.0M |
| Ratios | |||||
| Return on assets | -101.7% | -62.6% | -26.7% | -45.3% | -36.6% |
| Return on equity | -149.8% | -76.1% | -28.7% | -50.7% | -39.2% |
| Current ratio | 2.77 | 6.15 | 15.29 | 11.47 | 14.86 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 2,036,663 | $5.5M |
| Point72 Asset Management, L.P. | 246,615 | $663,394 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -11.48 (distress)
- Working capital / assets 0.537
- Retained earnings / assets -3.131
- EBIT / assets -1.043
- Equity / liabilities 2.113
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001759138 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.